276 related articles for article (PubMed ID: 31776413)
1. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
[TBL] [Abstract][Full Text] [Related]
3. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
4. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
5. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
6. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
7. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Jan; 9(1):655. PubMed ID: 30679757
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of
Satpati D; Sharma R; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Mar; 91(3):781-788. PubMed ID: 29130625
[TBL] [Abstract][Full Text] [Related]
10. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
11. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
12. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
14. HER3 PET Imaging:
Rinne SS; Leitao CD; Abouzayed A; Vorobyeva A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638277
[TBL] [Abstract][Full Text] [Related]
15. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.
Zhai C; Franssen GM; Petrik M; Laverman P; Summer D; Rangger C; Haubner R; Haas H; Decristoforo C
Mol Imaging Biol; 2016 Oct; 18(5):758-67. PubMed ID: 26905697
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
[TBL] [Abstract][Full Text] [Related]
18.
Satpati D; Vats K; Sharma R; Sarma HD; Dash A
J Pept Sci; 2020 Mar; 26(3):e3241. PubMed ID: 31984553
[TBL] [Abstract][Full Text] [Related]
19. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Rosestedt M; Andersson KG; Rinne SS; Leitao CD; Mitran B; Vorobyeva A; Ståhl S; Löfblom J; Tolmachev V; Orlova A
Sci Rep; 2019 May; 9(1):6779. PubMed ID: 31043683
[TBL] [Abstract][Full Text] [Related]
20. Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.
Da Pieve C; Allott L; Martins CD; Vardon A; Ciobota DM; Kramer-Marek G; Smith G
Bioconjug Chem; 2016 Aug; 27(8):1839-49. PubMed ID: 27357023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
